Zepatier treatment for 12 weeks, with or without ribavirin, was highly effective for induction of sustained virologic response in patients infected with hepatitis C genotypes 1, 4 or 6, who failed prior peg-interferon and ribavirin treatments, according to the results of the C-EDGE Treatment Experienced trial. SVR12 was also achieved by patients with cirrhosis or a null response to previous treatment in this trial, and the treatment was generally well tolerated.
To evaluate the effectiveness of elbasvir/grazoprevir in treatment-experienced patients infected with HCV genotypes 1, 4 or 6, Paul Y. Kwo, MD, FACG, FAASLD, of the division of gastroenterology/hepatology in the department of medicine at Stanford University School of Medicine, Palo Alto, Calif., and colleagues performed an international multicenter, open-label phase 3 randomized controlled trial of the drug regimen in this difficult to treat patient population
Continue reading...
No comments:
Post a Comment